Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir

Remdesivir (RDV) was the first antiviral drug approved by the FDA to treat severe coronavirus disease-2019 (COVID-19) patients. RDV inhibits SARS-CoV-2 replication by stalling the non structural protein 12 (nsp12) subunit of the RNA-dependent RNA polymerase (RdRp). No evidence of global widespread R...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos Bravo, Marta, Alonso, Rodrigo, Soria, Dafne, Sánchez Palomino, Sonsoles, Sanzo Machuca, Ángela, Rodríguez, Cristina, Alcamí, José, Díez-Fuertes, Francisco, Simarro Redon, Àlvar, Hurtado, Juan Carlos, Fernández Avilés, Francesc, Bodro, Marta, Rubio, Elisa, Villanueva, Jose Luis, Vergara, Andrea, Castro, Pedro, Tuset, Montserrat, Cuesta, Genoveva, Puerta, Pedro, García, Carolina, Mosquera Gutiérrez, María del Mar, Martínez, Miguel J., Vila, Jordi, Soriano, Alex, Marcos, María Ángeles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769853/
https://www.ncbi.nlm.nih.gov/pubmed/36354320
http://dx.doi.org/10.1128/spectrum.02448-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769853/
https://www.ncbi.nlm.nih.gov/pubmed/36354320
http://dx.doi.org/10.1128/spectrum.02448-22

Ejemplares similares